title: Ceramide inhibits axonal growth and nerve growth factor uptake without compromising the viability of sympathetic neurons.
abstract: Ceramide inhibits axonal growth of cultured rat sympathetic neurons when the ceramide content of distal axons, but not cell bodies, is increased (Posse de Chaves, E. I., Bussiere, M. Vance, D. E., Campenot, R. B., and Vance, J.E. (1997) J. Biol. Chem. 272, 3028-3035). We now report that inhibition of growth does not result from cell death since although ceramide is a known apoptotic agent, C(6)-ceramide given to the neurons for 24 h did not cause cell death but instead protected the neurons from death induced by deprivation of nerve growth factor (NGF). We also find that a pool of ceramide generated from sphingomyelin in distal axons, but not cell bodies, inhibits axonal growth. Analysis of endogenous sphingomyelinase activities demonstrated that distal axons are rich in neutral sphingomyelinase activity but contain almost no acidic sphingomyelinase, which is concentrated in cell bodies/proximal axons. Together, these observations are consistent with the idea that generation of ceramide from sphingomyelin by a neutral sphingomyelinase in axons inhibits axonal growth. Furthermore, we demonstrate that treatment of distal axons with ceramide inhibits the uptake of NGF and low density lipoproteins by distal axons by approximately 70 and 40%, respectively, suggesting that the inhibition of axonal growth by ceramide might be due, at least in part, to impaired endocytosis of NGF. However, inhibition of endocytosis of NGF by ceramide could not be ascribed to decreased phosphorylation of TrkA.
authors.affiliation: Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2S2, Canada.
authors.forename: E P
authors.initials: EP
authors.lastname: de Chaves
authors.forename: M
authors.initials: M
authors.lastname: Bussiere
authors.forename: B
authors.initials: B
authors.lastname: MacInnis
authors.forename: D E
authors.initials: DE
authors.lastname: Vance
authors.forename: R B
authors.initials: RB
authors.lastname: Campenot
authors.forename: J E
authors.initials: JE
authors.lastname: Vance
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001369:Axons / Q000187:drug effects*; D002352:Carrier Proteins / Q000378:metabolism; D016923:Cell Death; D002470:Cell Survival; D002478:Cells, Cultured; D002518:Ceramides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008077:Lipoproteins, LDL / Q000493:pharmacokinetics; D008565:Membrane Proteins / Q000378:metabolism; D020932:Nerve Growth Factor / Q000493:pharmacokinetics*; D009474:Neurons / Q000166:cytology*; D010766:Phosphorylation; D021381:Protein Transport; D051381:Rats; D017207:Rats, Sprague-Dawley; D020917:Receptor, trkA; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism; D013109:Sphingomyelins / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects
chemical_list: D002352:Carrier Proteins; D002518:Ceramides; D008077:Lipoproteins, LDL; D008565:Membrane Proteins; D013109:Sphingomyelins; C101954:N-caproylsphingosine; D020932:Nerve Growth Factor; D020917:Receptor, trkA; D013108:Sphingomyelin Phosphodiesterase